Lung transplant study tracks hidden virus breakthroughs
NCT ID NCT04439916
First seen Mar 17, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This study follows 40 lung transplant patients who are at high risk for CMV infection because the donor had CMV but the recipient did not. Researchers want to see how often the virus shows up in the blood while patients are taking the antiviral drug valganciclovir. They will also track side effects like low blood cell counts. The goal is to better understand these infections and improve care for future transplant patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alberta Hospital
RECRUITINGEdmonton, Alberta, T6G 2B7, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.